Table 1.
Patient and lymph-node stratification by molecular marker expression in lymph nodes.
| Molecular analysis | Molecular and histopathologic analysis | ||||||
|---|---|---|---|---|---|---|---|
| Target | Stratification by | molN0 | molN1 | molN0/pN0 | molN0/pN1 | molN1/pN0 | molN1/pN1 |
| KLK2a | Pat. n (%) | 56 (50.5) | 55 (49.5) | 56 (50.5) | 0 (0) | 27 (24.3) | 28 (25.2) |
| LN n (%) | 2197 (91.1) | 214 (8.9) | 2190 (90.8) | 7 (0.3) | 152 (6.3) | 62 (2.6) | |
| KLK3a | Pat. n (%b) | 51 (45.9) | 60 (54.1) | 51 (45.9) | 0 (0) | 32 (28.8) | 28 (25.2) |
| LN n (%b) | 2122 (88.0) | 289 (12.0) | 2116 (87.8) | 3 (0.1) | 223 (9.2) | 66 (2.7) | |
| KLK4a | Pat. n (%) | 54 (48.6) | 57 (51.4) | 52 (46.8) | 2 (1.8) | 31 (27.9) | 26 (23.4) |
| LN n (%) | 2221 (92.1) | 190 (7.9) | 2210 (91.7) | 11 (0.5) | 132 (5.5) | 58 (2.4) | |
| PSMAa | Pat. n (%) | 75 (67.6) | 36 (32.4) | 72 (64.9) | 3 (2.7) | 11 (9.9) | 25 (22.5) |
| LN n (%) | 2316 (96.1) | 95 (3.9) | 2300 (95.4) | 16 (0.7) | 42 (1.7) | 53 (2.2) | |
| TMPRSS2a | Pat. n (%) | 70 (63.1) | 41 (36.9) | 68 (61.3) | 2 (1.8) | 16 (14.4) | 25 (22.5) |
| LN n (%) | 2296 (95.2) | 115 (4.8) | 2283 (94.7) | 13 (0.5) | 59 (2.4) | 56 (2.3) | |
| TRPM8a | Pat. n (%) | 60 (54.1) | 51 (45.9) | 49 (44.1) | 2 (1.8) | 25 (22.5) | 26 (23.4) |
| LN n (%) | 2269 (94.1) | 142 (5.9) | 2256 (93.6) | 13 (0.5) | 86 (3.6) | 56 (2.3) | |
KLK2, KLK3, KLK4 Kallikrein 2, 3, and 4, PSMA prostate-specific membrane antigen, RP radical prostatectomy, TMPRSS2 transmembrane serine protease 2, TRPM8 transient receptor potential cation channel subfamily M member 8.
aThreshold calculated based on a gamma distribution to identify 99% of true histopathologic negative LNs with a 99% level of confidence.
bPercentages refer to percent of total.